SFL will host a panel discussion themed “From early diagnosis to access to treatment for are diseases – European and US perspectives” at the Swiss Biotech Day in Basel, Switzerland, on 25 April 2023 (14.30-15.15 CEST).

The panel will discuss the particularities of developing and bringing new innovative medicines for rare diseases to the market and to patients. Speakers will present regulatory perspectives for orphan drugs in Europe and the US, as well as market access considerations in Europe with a focus on Switzerland.

The panelists, Charlotte Chanson (Senior Director Global Diagnostics / Newborn Screening at Orchard), John Kirk (Vice-President Regulatory Affairs at Veristat), Anja Bührer (Vice-President Regulatory Affairs and Deputy CEO of SFL Group, a Veristat company) and Anna Ulbricht (Senior Director Medical Affairs and Market Access at SFL, a Veristat company) will share insights into newborn screening in Switzerland, the framework for orphan drug designation and approval in Europe and the US as well as insights on pricing and reimbursement of orphan drugs in Europe, with a focus on Switzerland. The discussion will be moderated by Nathalie Schober-Ladani (Senior Director Public Affairs and Regulatory Intelligence at SFL, a Veristat company).

The audience will have the opportunity to exchange with the panelists. You can already send us your questions by email to office@sfl-services.com by 12 April.

Register for the event here.